Baicalein induces apoptosis via a mitochondrial-dependent caspase activation pathway in T24 bladder cancer cells

Molecular Medicine Reports

Volumn 7, Issue 1, 2013, Pages 266-270

  Li, Hong Liang ^a   Zhang, Shu ^a   Wang, Yuan ^b   Liang, Rong Rui ^a   Li, Jun ^a   An, Peng ^a   Wang, Zi Ming ^a   Yang, Jun ^a   Li, Zong Fang ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b SHAANXI PROVINCIAL PEOPLE S HOSPITAL   (China)

Author keywords

Akt; Apoptosis; Baicalein; Bcl 2; Bladder cancer

Indexed keywords

ANTINEOPLASTIC AGENT; BAICALEIN; CASPASE 3; CASPASE 9; CYTOCHROME C; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER CELL; CANCER CELL T24; CANCER INHIBITION; DOWN REGULATION; ENZYME ACTIVATION; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; MITOCHONDRIAL MEMBRANE POTENTIAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR CELLS AND CELL LINES;

ANTIOXIDANTS; APOPTOSIS; CASPASE 3; CASPASE 9; CASPASES; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; FLAVANONES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIA; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION; TUMOR STEM CELL ASSAY; URINARY BLADDER NEOPLASMS;

EID: 84873873444     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2012.1123     Document Type: Article

References (29)

1. Bischoff CJ and Clark PE: Bladder cancer. Curr Opin Oncol21: 272-277, 2009.
2. Schenk-Braat EA and Bangma CH: Immunotherapy for superficial bladder cancer. Cancer Immunol Immunother 54: 414-423, 2005.
3. Shen Z, Shen T, Wientjes MG, O'Donnell MA and Au JL: Intravesical treatments of bladder cancer: review. Pharm Res25: 1500-1510, 2008.
4. Sekiya K and Okuda H: Selective inhibition of platelet lipoxygenase by baicalein. Biochem Biophys Res Commun105: 1090-1095, 1982.
5. Pidgeon GP, Kandouz M, Meram A and Honn KV: Mechanisms controlling cell cycle arrest and induction of apoptosis after 12-lipoxygenase inhibition in prostate cancer cells. Cancer Res62: 2721-2727, 2002.
6. Wong BC, Wang WP, Cho CH, Fan XM, Lin MC, Kung HF and Lam SK: 12-Lipoxygenase inhibition induced apoptosis in human gastric cancer cells. Carcinogenesis22: 1349-1354, 2001.
7. Chen SF, Hsu CW, Huang WH and Wang JY: Post-injury baicalein improves histological and functional outcomes and reduces inflammatory cytokines after experimental traumatic brain injury. Br J Pharmacol 155: 1279-1296, 2008.
8. Boyle SP, Doolan PJ, Andrews CE and Reid RG: Evaluation of quality control strategies in Scutellaria herbal medicines. J Pharm Biomed Anal 54: 951-957, 2011.
9. He XL, Wang YH, Gao M, Li XX, Zhang TT and DuGH: Baicalein protects rat brain mitochondria against chronic cerebral hypoperfusion-induced oxidative damage. Brain Res1249: 212-221, 2009.
10. Wang L, Ling Y, Chen Y, etal: Flavonoid baicalein suppresses adhesion, migration and invasion of MDA-MB-231 human breast cancer cells. Cancer Lett 297: 42-48, 2010.
11. Taniguchi H, Yoshida T, Horinaka M, etal: Baicalein overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance via two different cell-specific pathways in cancer cells but not in normal cells. Cancer Res 68: 8918-8927, 2008.
12. Chen CH, Huang LL, Huang CC, Lin CC, Lee Y and LuFJ: Baicalein, a novel apoptotic agent for hepatoma cell lines: a potential medicine for hepatoma. Nutr Cancer 38: 287-295, 2000.
13. Ma Z, Otsuyama K, Liu S, etal: Baicalein, a component of Scutellaria radix from Huang-Lian-Jie-Du-Tang (HLJDT), leads to suppression of proliferation and induction of apoptosis in human myeloma cells. Blood 105: 3312-3318, 2005.
14. Carnero A: The PKB/AKT pathway in cancer. Curr Pharm Des16: 34-44, 2010.
15. Czabotar PE and Lessene G: Bcl-2 family proteins as therapeutic targets. Curr Pharm Des 16: 3132-3148, 2010.
16. Kirkin V, Joos S and Zörnig M: The role of Bcl-2 family members in tumorigenesis. Biochim Biophys Acta 1644: 229-249, 2004.
17. Malaguarnera L: Implications of apoptosis regulators in tumorigenesis. Cancer Metastasis Rev 23: 367-387, 2004.
18. Tsujimoto Y and Shimizu S: Role of the mitochondrial membrane permeability transition in cell death. Apoptosis 12: 835-840, 2007.
19. Hengartner MO: The biochemistry of apoptosis. Nature407: 770-776, 2000.
20. Goswami A, Ranganathan P and Rangnekar VM: The phosphoinositide 3-kinase/Akt1/Par-4 axis: a cancer-selective therapeutic target. Cancer Res 66: 2889-2892, 2006.
21. Chen M, Gu J, Delclos GL, Killary AM, etal: Genetic variations of the PI3K-AKT-mTOR pathway and clinical outcome in muscle invasive and metastatic bladder cancer patients. Carcinogenesis31: 1387-1391, 2010.
22. Jiang BH and Liu LZ: PI3K/PTEN signaling in angiogenesis and tumorigenesis. Adv Cancer Res 102: 19-65, 2009.
23. Hartmann W, Küchler J, Koch A, etal: Activation of phosphatidylinositol-3'-kinase/AKT signaling is essential in hepatoblastoma survival. Clin Cancer Res 15: 4538-4545, 2009.
24. Danial NN: BCL-2 family proteins: critical checkpoints of apoptotic cell death. Clin Cancer Res 13: 7254-7263, 2007.
25. Yang J, Liu X, Bhalla K, etal: Prevention of apoptosis by Bcl-2: Release of cytochrome c from mitochondria blocked. Science275: 1129-1132, 1997.
26. Skommer J, Brittain T and Raychaudhuri S: Bcl-2 inhibits apoptosis by increasing the time-to-death and intrinsic cell-to-cell variations in the mitochondrial pathway of cell death. Apoptosis15: 1223-1233, 2010.
27. Zhao Y, Zhang CL, Zeng BF, Wu XS, Gao TT and Oda Y: Enhanced chemosensitivity of drug-resistant osteosarcoma cells by lentivirus-mediated Bcl-2 silencing. Biochem Biophys Res Commun390: 642-647, 2009.
28. Reagan-Shaw S, Nihal M, Ahsan H, Mukhtar H and Ahmad N: Combination of vitamin E and selenium causes an induction of apoptosis of human prostate cancer cells by enhancing Bax/Bcl-2 ratio. Prostate 68: 1624-1634, 2008.
29. Katiyar SK, Roy AM and Baliga MS: Silymarin induces apoptosis primarily through a p53-dependent pathway involving Bcl-2/Bax, cytochrome c release, and caspase activation. Mol Cancer Ther 4: 207-216, 2005.